The Covid-19 vaccine from Astrazeneca has taken some hits since last week, when the European Medicines Agency (EMA) confirmed that the EMA's safety experts sees a possible connection between this vaccine and a series of rare but highly serious, and sometimes fatal, side effects.
Even though many countries have limited their use of the vaccine, and some – like Denmark – have opted to suspend it immediately, it does not seem like this will have any financial consequences for Astrazeneca. This firm runs all of its global vaccine sales as a non-profit project, and the company is regretful about the fact that people seem to forget this, as criticism is raining down on Astrazeneca in relation to the possible side effects of the vaccine on the one hand, and overdue deliveries on the other.
Get full access for you and your coworkers.
Start a free company trial todayAlready a member? Log in.
More from MedWatch
More disappointment for Orphazyme as FDA rejects Niemann Pick C application
The FDA have rejected an application for marketing authorization for Orphazyme's main drug candidate, arimoclomol, as a treatment for metabolic disease Niemann Pick C. The authority wants more data.
Orphazyme CEO silent on potential firings in wake of FDA rejection
The FDA rejection of Orphazyme's drug candidate in its main indication will trigger major cuts at the biotech firm, but CEO Christophe Bourdon has no comment on where they will be implemented and how hard the US organization will be hit.
Orphazyme cuts guidance following FDA setback
Friday's disappointing rejection letter from the US FDA is affecting Orphazyme's guidance for 2021. Now, the biotech firm forecasts an operating deficit of DKK 670-700m, up from DKK 100-150m.
Top Orphazyme figure on FDA rejection: "It is very disappointing and very unexpected"
Biotech heavyweight Bo Jesper Hansen is very disappointed over the FDA rejection of Orphazyme's only drug candidate.
US OTC hearing aid channel back on Department of Health agenda
The US health department aims to have a hearing on publishing the regulatory framework for selling hearing aids over the course of the year.
Radiochemist in CMC Development - Y-mAbs Therapeutics 
Senior Manager, IT QA - Genmab 
Senior CMC Expert/Senior CMC Project Manager - Klifo 
Senior Clinical Development Scientist/Physician - Lundbeck 
Chemist responsible for validation and qualification for Laboratory Automation Development 
(Senior) Regulatory Science Specialist - IWA Consulting 
Regulatory affairs life cycle specialist 
Associate Formulation Scientist, Oral Formulation Research - Novo Nordisk 
Employee for regulatory department 
Analytical Coordinator (Senior scientist) – Permanent position, Symphogen